SREBPs play important roles in the regulation of lipid metabolism, and are closely related to the occurrence and development of many metabolic diseases. Small molecular inhibitors of SERBPs are important tools in developing efficient treatment of metabolic diseases. However, there are no listing drug targeting SREBPs. Therefore, there is an urgent need to develop highly specific small molecules that inhibit SREBPs. In this study, using a hepatocyte-based high-throughput screening, we identified anhydroicaritin (AHI) as a novel inhibitor of SREBPs. HepG2, HL-7702, and human primary hepatocytes were used to verify the effects of AHI. We explored the mechanism by which AHI blocks the binding of SCAP/SREBPs complex with Sec23α/24D via regulating LKB1/AMPK/mTOR pathway. AHI reduced liver cell lipid level by preventing de novo lipogenesis. In diet induced obese mice, AHI ameliorated obesity, insulin resistance, fatty accumulation in liver and hyperlipemia. In conclusion, AHI improves diet-induced obesity and alleviates insulin resistance by suppressing SREBPs maturation which is dependent on LKB1/AMPK/mTOR pathway. Thus, AHI can serve as a leading compound for pharmacological control of metabolic diseases.
Keywords: 25-Hydroxycholesterol (PubChem CID: 65094); 3,5-Dihydroxy-4′-methoxy-6″,6″-dimethyl-4″,5″-dihydropyrano(2″,3″:7,8)-flavone (PubChem CID: 14583584); Anhydroicaritin; Anhydroicaritin (PubChem CID: 5318980); Compound C (PubChem CID: 11524144); Epimedin A (PubChem CID: 24721194); Epimedin B (PubChem CID: 5748393); Epimedin C (PubChem CID: 5748394); Hyperlipidemia; Icariin (PubChem CID: 5318997); Icarisid I (PubChem CID: 5745470); Icarisid II (PubChem CID: 5488822); Icaritin (PubChem CID: 14427423); Insulin resistance; Isoanhydroicaritin (PubChem CID: 5322079); Lovastatin (PubChem CID: 53232); MHY1485 (PubChem CID: 2834965); Obesity; Rapamycin (PubChem CID: 5284616); SREBPs.
Copyright © 2016 Elsevier Inc. All rights reserved.